
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN (BBV152)
MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) this week announced positive results from the Phase 2/3, observer-blind, immuno-bridging and broadening study of its COVID-19 vaccine candidate, COVAXINâ„¢ (BBV152; Clinicaltrials.gov, NCT05258669), …
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN (BBV152) Read More